Enzolytics Inc (ENZC)

[OTCShotCaller]

Good post and good question.

BMS-378806 is a prototype HIV Inhibitor class chemical compound under development by Bristol-Meyer Squibb shown to inhibit the entry of HIV-1 into CD4 cells thereby having the capacity to reduce Viral Load.

There are already dozens of medications on the market that do the same thing that are the current industry standard for treating HIV patients, i.e. the classic Antiretroviral Therapy (ART) drug combination treatment administered 3X per week that carry considerable side effects and often result in a host of co-morbid conditions resulting from the treatment itself.

There are more than two dozen ART Therapy drugs on the market that fall into six main types. Each of these drugs fights the HIV Virus in different ways and are typically administered in combination with each other, or in a "cocktail" that's been shown to control HIV and/or lower the possibility that the HIV virus will become treatment resistant.

Treating physicians typically recommend HIV patients to that take three different medicines from the ART line up of two different class of drugs prescribed for ART Therapy which are too many to list here.

Available data on BMS-378806 which is limited has not described its capacity to prevent "Viral Escape" nor its effectiveness in multiple strains of HIV-1 sub-types. Therefore it is far inferior to Clone-3 as are ALL Art Therapy drugs presently on the market.

"BMS" means Bristol-Myer Squibb who owns the Patent on this compound dating back to or prior to 2004 when the first publication(s) on data performance began to appear. It has not yet been brought to market by BMS as an available pharmaceutical. Since data is limited, as are research publications, it might no longer be under development by BMS.

https://pubmed.ncbi.nlm.nih.gov/15180540/

I hope this helps to answer your question.

Be well and prosper...